Valbiotis publishes scientific advances on TOTUM-448

The French pharmaceutical company Valbiotis has announced a new scientific publication concerning TOTUM-448, an active ingredient used to treat metabolic liver diseases. The article was published in the international journal Scientific Reports. This is the first study to present results obtained in humans, confirming the bioavailability and describing the mechanism of action of TOTUM-448 on human liver cells.

This publication, the result of collaborations with institutions such as Clinic'n'Cell and the University of Bordeaux, highlights the potential of TOTUM-448 to reduce intracellular lipids and inflammation. The development of TOTUM-448 is part of the ValbiotisPRO® range, with planned rollout in France, Asia, and the Middle East thanks to recent distribution agreements.